Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER) A Phase I Safety Clinical Trial

Overview of attention for article published in CHEST, November 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

news: 1 news outlet
twitter: 8 X users

patent: 7 patents
facebook: 1 Facebook page

Readers on

mendeley: 211 Mendeley

So far, Altmetric has seen 8 X posts from 8 X users, with an upper bound of 92,822 followers.

Mesenchymal stem cells may be safe in pulmonary fibrosis. #journalCHEST https://t.co/CKDNnOuNso

Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary #Fibrosis via Intravenous https://t.co/0WqTNK684A @accpchest https://t.co/2sw8TOPOto

RT @KaminskiMed: Phase I: human mesenchymal stem cells in idiopathic pulmonary fibrosis @RCMBStemCell @StemCellMarket thoughts? https://…

@FibrosisPulmon ar. De nuevo tratamiento de células madres? https://t.co/OShswjYmer

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 4 additional X posts.